Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer

Clinica Chimica Acta

Volumn 430, Issue , 2014, Pages 86-91

  Di Gioia, Dorit ^a   Dresse, Marie ^a   Mayr, Doris ^a   Nagel, Dorothea ^a   Heinemann, Volker ^a   Kahlert, Steffen ^a   Stieber, Petra ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Breast cancer; Healthy individuals; HER2 ECD; HER2 neu; Shed antigen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; VERY ELDERLY; BLOOD; BREAST NEOPLASMS; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOCHEMISTRY; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; TIME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84893146014     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.12.036     Document Type: Article

References (37)

1. Baselga J. Is circulating HER-2 more than just a tumor marker?. Clin Cancer Res 2001, 7:2605-2607.
2. Yamauchi H., Stearns V., Hayes D.F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001, 19:2334-2356.
3. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
4. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S., Price C.P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003, 49:1579-1598.
5. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S., Price C.P. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 2004, 5:105-116.
6. Molina R., Jo J., Filella X., et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 1997, 18:188-196.
7. Perez E.A., Romond E.H., Suman V.J., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011, 29:3366-3373.
8. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
9. Harris L., Luftner D., Jager W., Robertson J.F. c-erbB-2 in serum of patients with breast cancer. Int J Biol Markers 1999, 14:8-15.
10. Yamauchi H., O'Neill A., Gelman R., et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997, 15:2518-2525.
11. Petersen E.R., Sorensen P.D., Jakobsen E.H., Madsen J.S., Brandslund I. Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer. Clin Chem Lab Med 2013, 1-10.
12. Ali S.M., Carney W.P., Esteva F.J., et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008, 113:1294-1301.
13. Perez E.A., Suman V.J., Davidson N.E., et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006, 24:3032-3038.
14. Fergenbaum J.H., Garcia-Closas M., Hewitt S.M., Lissowska J., Sakoda L.C., Sherman M.E. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 2004, 13:667-672.
15. Leary A.F., Hanna W.M., van de Vijver M.J., et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 2009, 27:1694-1705.
16. Jensen B.V., Johansen J.S., Price P.A. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003, 9:4423-4434.
17. Meden H., Mielke S., Marx D., Wuttke W., Kuhn W. Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res 1997, 17:3075-3077.
18. Meden H., Mielke S., Schauer A., Kuhn W. Serum levels of the c-erbB-2 (HER2/neu) encoded oncoprotein fragment p105 in normal pregnancies. In Vivo 1997, 11:51-54.
19. Di Cosimo S., Alimonti A., Ferretti G., et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol 2004, 15:1065-1071.
20. Willsher P.C., Beaver J., Pinder S., et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996, 40:251-255.
21. Breuer B., Smith S., Thor A., et al. ErbB-2 protein in sera and tumors of breast cancer patients. Breast Cancer Res Treat 1998, 49:261-270.
22. Pallud C., Guinebretiere J.M., Guepratte S., et al. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. Anticancer Res 2005, 25:1433-1440.
23. Imoto S., Wada N., Hasebe T., Ochiai A., Kitoh T. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast. Int J Cancer 2007, 120:357-361.
24. Molina R., Jo J., Filella X., et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998, 51:109-119.
25. Ludovini V., Gori S., Colozza M., et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 2008, 19:883-890.
26. Kong S.Y., Kang J.H., Kwon Y., et al. Serum HER-2 concentration in patients with primary breast cancer. J Clin Pathol 2006, 59:373-376.
27. Lipton A., Ali S.M., Leitzel K., et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002, 20:1467-1472.
28. Hayes D.F., Yamauchi H., Broadwater G., et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001, 7:2703-2711.
29. Kong S.Y., Nam B.H., Lee K.S., et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem 2006, 52:1510-1515.
30. Ali S.M., Leitzel K., Chinchilli V.M., et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 2002, 48:1314-1320.
31. Dittadi R., Zancan M., Perasole A., Gion M. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers 2001, 16:255-261.
32. Molina R., Auge J.M., Escudero J.M., et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol 2010, 31:171-180.
33. Kong Y., Dai S., Xie X., et al. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol 2012, 138:275-284.
34. Codony-Servat J., Albanell J., Lopez-Talavera J.C., Arribas J., Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999, 59:1196-1201.
35. Molina R., Filella X., Zanon G., et al. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res 2003, 23:1043-1050.
36. Molina R., Escudero J.M., Munoz M., Auge J.M., Filella X. Circulating levels of HER-2/neu oncoprotein in breast cancer. Clin Chem Lab Med 2012, 50:5-21.
37. Sorensen P.D., Jakobsen E.H., Langkjer S.T., et al. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin Chem Lab Med 2009, 47:1117-1123.